July 13, 2021
Evgen Pharma makes progress on two fronts in the field of cancer
Featured News: Stalicla licensing deal
Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla
Read More
October 10, 2022
Filter by:
Regulatory News
Media Coverage
Videos
Date
Title
Download
April 7, 2021
Evgen Pharma: Johns Hopkins research further assesses the potential of company’s drug to treat COVID-19
March 23, 2021
Going for Growth: Evgen Pharma CEO, Huw Jones, interviewed by ShareBuyers
March 9, 2021
Evgen Pharma now has the financial runway to exploit its technology after ‘transformative’ City fundraiser
June 13, 2018
Evgen Pharma Encouraging interim data from the STEM trial
Date
Title
Download
March 23, 2023
Evgen Pharma presents at the Proactive One2One Investor Forum
March 23, 2023
Investor Meet Company Presentation
December 13, 2022
Evgen Pharma “cash runway in pretty good shape”
December 9, 2022
Interim Results 2022-23
October 12, 2022
Evgen Pharma Licensing and Clinical Programme Update
July 22, 2022
Evgen Pharma Post AGM Presentation
June 16, 2022
Evgen Pharma talks through clinical milestones and financial results from its 2022 full-year report
January 26, 2022
Evgen Pharma presents 2022 clinical trials plans and progress with US and UK regulators
July 22, 2021
Evgen portfolio update on core field of cancer, ‘the R&D is entirely on plan and on budget’
January 26, 2021
Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug
December 16, 2020
Evgen Pharma have ‘many shots at goal’, solving unmet needs in the pharmaceutical industry